ArticleThe journals of gerontology. Series A, Biological sciences and medical sciences2016
Rapamycin Increases Mortality in db/db Mice, a Mouse Model of Type 2 Diabetes.
Article in The journals of gerontology. Series A, Biological sciences and medical sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Rapamycin, Not Metformin, Mirrors Dietary Restriction-Driven Lifespan Extension in Vertebrates: A Meta-Analysis.Aging cell · 2025Pooled it
- Cell-based screen identifies translation state modulators that extend lifespan in Drosophila melanogaster and Caenorhabditis elegans.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Article
- Glycation-lowering compounds inhibit ghrelin signaling to reduce food intake, lower insulin resistance, and extend lifespan.Cell reports · 2025Article
- p53 and TIGAR promote redox control to protect against metabolic dysfunction-associated steatohepatitis.JHEP reports : innovation in hepatology · 2025Article
- Enhancing immunity during ageing by targeting interactions within the tissue environment.Nature reviews. Drug discovery · 2025Review
- Article
- Targeting the biology of aging with mTOR inhibitors.Nature aging · 2023Review
- Rapamycin, the only drug that has been consistently demonstrated to increase mammalian longevity. An update.Experimental gerontology · 2023Review
- Cellular Metabolism: A Fundamental Component of Degeneration in the Nervous System.Biomolecules · 2023Review
- Article
- The Metabolic Basis for Nervous System Dysfunction in Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease.Current neurovascular research · 2023Article
- Obesity and Risk for Lymphoma: Possible Role of Leptin.International journal of molecular sciences · 2022Review
- Age-dependent sex difference of non-alcoholic fatty liver disease in TSOD and db/db mice.PloS one · 2022Article
- Cerebral endothelial cell derived small extracellular vesicles improve cognitive function in aged diabetic rats.Frontiers in aging neuroscience · 2022Article
- Current Status of Autophagy Enhancers in Metabolic Disorders and Other Diseases.Frontiers in cell and developmental biology · 2022Review
- Autophagy in metabolic disease and ageing.Nature reviews. Endocrinology · 2021Review
- Effect of rapamycin on aging and age-related diseases-past and future.GeroScience · 2021Review
- Agriophyllum Oligosaccharides Ameliorate Diabetic Insulin Resistance Through INS-R/IRS/Glut4-Mediated Insulin Pathway in db/db Mice and MIN6 Cells.Frontiers in pharmacology · 2021Article
- Nicotinamide as a Foundation for Treating Neurodegenerative Disease and Metabolic Disorders.Current neurovascular research · 2021Review
- The Discovery of Druggable Anti-aging Agents.Annals of geriatric medicine and research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 1 country.
Funding
Abstract
We examined the effect of rapamycin on the life span of a mouse model of type 2 diabetes, db/db mice. At 4 months of age, male and female C57BLKSJ-lepr (db/db) mice (db/db) were placed on either a control diet, lacking rapamycin or a diet containing rapamycin and maintained on these diets over their life span. Rapamycin was found to reduce the life span of the db/db mice. The median survival of male db/db mice fed the control and rapamycin diets was 349 and 302 days, respectively, and the median survival of female db/db mice fed the control and rapamycin diets was 487 and 411 days, respectively. Adjusting for gender differences, rapamycin increased the mortality risk 1.7-fold in both male and female db/db mice. End-of-life pathological data showed that suppurative inflammation was the main cause of death in the db/db mice, which is enhanced slightly by rapamycin treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.